查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1859021

痤瘡藥物市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

Acne Medication Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 146 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球痤瘡藥物市場價值為 111 億美元，預計到 2034 年將以 5.3% 的複合年成長率成長至 184 億美元。

痤瘡藥物市場 - IMG1

痤瘡病例的增加，尤其是在15至19歲的青少年群體中，推動了市場擴張，也刺激了對有效痤瘡治療的需求。生活方式的改變、荷爾蒙失衡和環境壓力也是加劇痤瘡流行、導致口服和外用藥物需求增加的因素。此外，皮膚油脂分泌過多和毛囊受刺激引起的白頭粉刺激增，也進一步推動了市場成長。痤瘡藥物屬於皮膚科範疇，主要針對尋常性痤瘡——一種涉及毛孔堵塞、白頭粉刺、黑頭粉刺和各種皮損的慢性發炎性疾病。治療旨在減輕發炎、調節皮脂分泌和抑制細菌生長。隨著對不含防腐劑、減少類固醇和清潔標籤配方的需求不斷成長，市場也在不斷發展，這些配方可以提高患者的依從性並減少副作用。此外，遠距醫療和電子商務平台的興起也提高了尋求痤瘡解決方案的患者獲得治療的便利性和參與度。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 111億美元
預測值 184億美元
複合年成長率 5.3%

2024年，外用藥物佔據了73.3%的市場佔有率，這主要得益於其使用方便且對輕度至中度痤瘡的療效。此類別包括乳膏、乳液、貼片和濕紙巾，可將活性成分直接輸送到患處，最大限度地減少全身副作用，同時滿足不同膚質的需求。諸如活性成分微囊包裹、泡沫配方和水膠體貼片等創新技術正在提升治療效果和使用者依從性。皮膚科醫生通常將外用藥物作為一線治療方案，它們在多步驟護膚流程中的作用也鞏固了其在臨床和消費者痤瘡治療中的重要性。

2024年，發炎性痤瘡市場規模預計將達到87億美元，這主要得益於此類痤瘡的嚴重性以及對標靶治療的需求。該市場涵蓋丘疹、膿皰、結節和囊腫等症狀，通常需要局部和全身治療相結合。治療重點在於緩解中重度痤瘡相關的發炎、紅腫和細菌感染。人們對早期介入以預防疤痕形成的認知不斷提高，也加速了處方藥在發炎性痤瘡治療中的應用。

2024年，北美痤瘡藥物市佔率達到39.7%。該地區的成長主要源於尋常性痤瘡的高發病率，以及完善的醫療基礎設施和人們對有效痤瘡治療意識的不斷提高。美國、加拿大和墨西哥等國家是推動區域需求的主要力量，受益於個人化皮膚病學等技術的進步，該技術結合了基因組分析，可實現更精準的治療。公共衛生宣傳活動以及處方藥和非處方藥消費量的成長進一步促進了市場擴張。

全球痤瘡藥物市場的主要參與者包括拜耳、施泰福（葛蘭素史克）、魯賓製藥、梯瓦製藥、博士倫、帕拉泰克製藥、高德美、瑞迪博士實驗室、阿科恩、太陽製藥、艾爾建（艾伯維）、梅恩製藥、艾爾米拉爾、利潔時和托倫特製藥。為了鞏固市場地位，痤瘡藥物市場的企業專注於創新，開發先進配方，例如不含防腐劑和減少類固醇的產品，以改善患者療效並減少副作用。他們也正在拓展產品組合，涵蓋針對不同類型痤瘡的口服和外用療法。與醫療保健提供者建立策略合作夥伴關係，並投資於遠距醫療和電子商務等數位平台，有助於提高產品的可及性和患者參與度。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

  • 產業生態系分析
    • 供應商格局
    • 每個階段的價值增加
    • 影響價值鏈的因素
  • 產業影響因素
    • 成長促進因素
      • 尋常性痤瘡盛行率不斷上升
      • 生活方式和環境誘因
      • 皮膚科製劑的進展
      • 人們對醫療保健的認知和獲取途徑不斷提高
    • 產業陷阱與挑戰
      • 治療相關副作用和抗藥性
      • 服務不足地區的接入有限
    • 市場機遇
      • 基於微生物組和荷爾蒙標靶療法的創新
      • 人工智慧驅動的護膚和個人化護理方案的拓展
  • 成長潛力分析
  • 監管環境
  • 未來市場趨勢
  • 技術格局
    • 目前技術
    • 新興技術
  • 專利分析
  • 報銷方案
  • 管道分析
  • 定價分析
  • 波特的分析
  • PESTEL 分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估算與預測：依產品分類，2021-2034年

  • 主要趨勢
  • 維他命A酸
  • 抗生素
  • 水楊酸
  • 過氧化芐
  • 壬二酸
  • 其他產品

第6章：市場估價與預測：依配方分類，2021-2034年

  • 主要趨勢
  • 主題
    • 乳霜和乳液
    • 補丁和擦拭墊
  • 口服
    • 片劑和膠囊
    • 粉末
    • 液體

第7章：市場估算與預測：依痤瘡類型分類，2021-2034年

  • 主要趨勢
  • 發炎性痤瘡
  • 非發炎性痤瘡

第8章：市場估算與預測：依類型分類，2021-2034年

  • 主要趨勢
  • 處方藥
  • 非處方藥

第9章：市場估計與預測：依年齡層別分類，2021-2034年

  • 主要趨勢
  • 12至18
  • 19至35歲
  • 35歲以上

第10章：市場估價與預測：依配銷通路，2021-2034年

  • 主要趨勢
  • 離線頻道
    • 零售商店
    • 藥房和藥品商店
    • 皮膚科診所/醫院
  • 線上管道

第11章：市場估計與預測：按地區分類，2021-2034年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第12章：公司簡介

  • Akorn
  • Allergan (AbbVie)
  • Almirall SA
  • Bausch Health
  • Bayer
  • Dr. Reddy's Laboratories
  • Galderma
  • Lupin Pharmaceuticals
  • Mayne Pharmaceuticals
  • Paratek Pharmaceuticals
  • Reckitt Benckiser
  • Stiefel (GSK)
  • Sun Pharmaceutical
  • Teva Pharmaceuticals
  • Torrent Pharmaceuticals
  • Viatris
簡介目錄
Product Code: 3010

The Global Acne Medication Market was valued at USD 11.1 billion in 2024 and is estimated to grow at a CAGR of 5.3% to reach USD 18.4 billion by 2034.

Acne Medication Market - IMG1

The expansion is driven by increasing acne cases, particularly among teenagers aged 15 to 19, which fuels the demand for effective acne treatments. Lifestyle changes, hormonal imbalances, and environmental stressors are also contributing factors that intensify acne prevalence, leading to a higher need for both oral and topical medications. Additionally, the surge in whiteheads caused by oily skin and irritated hair follicles is pushing market growth further. The acne medication segment falls within dermatology, focusing on managing acne vulgaris a chronic inflammatory condition involving clogged pores, whiteheads, blackheads, and various lesions. Treatments aim to reduce inflammation, regulate sebum production, and inhibit bacterial growth. The market is also evolving with the rising demand for preservative-free, steroid-sparing, and clean-label formulations that enhance patient compliance and reduce side effects. Furthermore, the rise of telehealth and e-commerce platforms is improving accessibility and engagement for patients seeking acne solutions.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$11.1 Billion
Forecast Value$18.4 Billion
CAGR5.3%

In 2024, the topical medication segment held 73.3% share, owing to its ease of application and effectiveness in treating mild to moderate acne. This category includes creams, lotions, patches, and wipes that deliver active ingredients directly to the affected skin, minimizing systemic side effects while catering to diverse skin types. Innovations such as encapsulated actives, foam formulations, and hydrocolloid patches are boosting treatment effectiveness and user adherence. Dermatologists commonly prescribe topical treatments as first-line therapy, and their role in multi-step skincare routines has cemented their importance in both clinical and consumer acne care.

The inflammatory acne segment generated USD 8.7 billion in 2024, driven by the severity of this acne type and the need for targeted treatment. This segment covers conditions like papules, pustules, nodules, and cysts, which often require a combination of topical and systemic therapies. Treatments focus on alleviating inflammation, redness, swelling, and bacterial infection associated with moderate to severe acne. Growing awareness about early intervention to prevent scarring has also accelerated the use of prescription medications in managing inflammatory acne.

North America Acne Medication Market held a 39.7% share in 2024. The region's growth stems from the high prevalence of acne vulgaris, supported by strong healthcare infrastructure and rising awareness about effective acne management. Countries including the United States, Canada, and Mexico drive regional demand, benefiting from advancements like personalized dermatology, which incorporates genomic profiling for more precise treatments. Public health campaigns and increasing consumption of both prescription and over-the-counter products further bolster market expansion.

Leading players in the Global Acne Medication Market include Bayer, Stiefel (GSK), Lupin Pharmaceuticals, Teva Pharmaceuticals, Bausch Health, Paratek Pharmaceuticals, Galderma, Dr. Reddy's Laboratories, Akorn, Sun Pharmaceutical, Allergan (AbbVie), Mayne Pharmaceuticals, Almirall, Reckitt Benckiser, and Torrent Pharmaceuticals. To strengthen their position, companies in the Acne Medication Market focus on innovation through the development of advanced formulations like preservative-free and steroid-sparing products, which improve patient outcomes and reduce side effects. They are also expanding their portfolios to include oral and topical therapies targeting diverse acne types. Strategic partnerships with healthcare providers and investment in digital platforms such as telehealth and e-commerce enhance product accessibility and patient engagement.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumption and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Formulation trends
    • 2.2.4 Acne type trends
    • 2.2.5 Type trends
    • 2.2.6 Age group trends
    • 2.2.7 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of acne vulgaris
      • 3.2.1.2 Lifestyle and environmental triggers
      • 3.2.1.3 Advancements in dermatological formulations
      • 3.2.1.4 Growing awareness and access to care
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Treatment-related side effects and resistance
      • 3.2.2.2 Limited access in underserved regions
    • 3.2.3 Market opportunities
      • 3.2.3.1 Innovation in microbiome-based and hormone-targeted therapies
      • 3.2.3.2 Expansion of AI-driven skincare and personalized regimens
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Future market trends
  • 3.6 Technological landscape
    • 3.6.1 Current technologies
    • 3.6.2 Emerging technologies
  • 3.7 Patent analysis
  • 3.8 Reimbursement scenario
  • 3.9 Pipeline analysis
  • 3.10 Pricing analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Retinoids
  • 5.3 Antibiotics
  • 5.4 Salicylic acid
  • 5.5 Benzyl peroxide
  • 5.6 Azelaic acid
  • 5.7 Other products

Chapter 6 Market Estimates and Forecast, By Formulation, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Topical
    • 6.2.1 Creams and lotions
    • 6.2.2 Patches and wiping pads
  • 6.3 Oral
    • 6.3.1 Tablets and capsules
    • 6.3.2 Powders
    • 6.3.3 Liquids

Chapter 7 Market Estimates and Forecast, By Acne Type, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Inflammatory acne
  • 7.3 Non-inflammatory acne

Chapter 8 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prescription drugs
  • 8.3 Over the counter drugs

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 12 to 18
  • 9.3 19 to 35
  • 9.4 Above 35

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 Offline channels
    • 10.2.1 Retail stores
    • 10.2.2 Pharmacies and drug stores
    • 10.2.3 Dermatology clinics/hospitals
  • 10.3 Online channels

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 11.1 Key trends
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 France
    • 11.3.4 Spain
    • 11.3.5 Italy
    • 11.3.6 Netherlands
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 South Korea
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Argentina
  • 11.6 Middle East and Africa
    • 11.6.1 South Africa
    • 11.6.2 Saudi Arabia
    • 11.6.3 UAE

Chapter 12 Company Profiles

  • 12.1 Akorn
  • 12.2 Allergan (AbbVie)
  • 12.3 Almirall S.A.
  • 12.4 Bausch Health
  • 12.5 Bayer
  • 12.6 Dr. Reddy’s Laboratories
  • 12.7 Galderma
  • 12.8 Lupin Pharmaceuticals
  • 12.9 Mayne Pharmaceuticals
  • 12.10 Paratek Pharmaceuticals
  • 12.11 Reckitt Benckiser
  • 12.12 Stiefel (GSK)
  • 12.13 Sun Pharmaceutical
  • 12.14 Teva Pharmaceuticals
  • 12.15 Torrent Pharmaceuticals
  • 12.16 Viatris